Used in cancer research, particularly in studies involving triple-negative breast cancer. It was investigated for its ability to inhibit poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. By blocking this enzyme, the compound aimed to enhance the effectiveness of chemotherapy agents like gemcitabine and carboplatin, making cancer cells more susceptible to damage and death. Although it showed promise in early trials, later clinical studies did not confirm significant efficacy, leading to discontinuation of further development for this indication.